Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Asunercept for Severe COVID-19
NCT04535674Phase 2Completed
- Sponsor
- Apogenix
- Start
- Oct 2020
- Primary completion
- Oct 2021
- Modality
- Fc-Fusion Proteins
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of asunercept in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Apogenix. Primary endpoint: Time to sustained clinical improvement of one category. Started Oct 2020; status: completed.
02
Drugs
asunercept
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04535674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04535674.